ASX Linkedin Twitter               

 

Analyst Coverage 2014

Bioshares Edition 582
19 December 2014
Top Six Stock Picks – 2015

Bioshares Edition 579
28 November 2014
Viralytics – An Overlooked Investment Opportunity

Bell Potter
1 December 2014
Follow up Trial to CALM Approaching

BBY
17 November 2014
Harnessing an oncolytic virus to kill cancer cells

Bioshares Edition 574
24 October 2014
Viralytics and the Next Wave of Cancer Immunotherapies

Bell Potter
17 July 2014
Melanoma therapy development gathering steam

OzEquities
4 Jul 2014
Viralytics overview and current Phase 2 Clinical Trial promising results

Edison
5 Jun 2014
Keep CALM and carry on

Edison
14 Apr 2014
STORMing start to a transformational year ahead

Bioshares Edition 542
7 March 2014
Viralytics Starts Phase I/II Storm Study With Intravenous Cavatak

Bell Potter
24 February 2014
CAVATAK on the ATTACK

Bioshares Edition 537
31 January 2014
Viralytics cashes up

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).